AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

AbCellera Biologics Inc. (ABCL) reported $9.18 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 57.4%. EPS of -$0.17 for the same period compares to -$0.10 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $9.58 million, representing a surprise of -4.19%. The company delivered an EPS surprise of -21.43%, with the consensus EPS estimate being -$0.14.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how AbCellera Biologics Inc. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenue- Research fees: $8.74 million versus $8.34 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -23.5% change.
  • Revenue- Licensing: $0.19 million versus $0.32 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +12.1% change.
  • Revenue- Milestone payments: $0.25 million versus $1.16 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -50% change.
View all Key Company Metrics for AbCellera Biologics Inc. here>>>

Shares of AbCellera Biologics Inc. have returned -3.1% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Just Released: Zacks Top 10 Stocks for 2024

Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.

See New Top 10 Stocks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AbCellera Biologics Inc. (ABCL) : Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.